Johnson & Johnson (JNJ) Land & Improvements (2011 - 2012)
Johnson & Johnson recorded quarterly Land & Improvements of $754.0 million in Q1 2012, up 2.17% quarter-over-quarter from $738.0 million in Q1 2011, and up 2.17% year-over-year from $738.0 million in Q1 2011.
Johnson & Johnson's Land & Improvements history runs 2 years deep, the most recent figure standing at $754.0 million for Q1 2012.
- In Q1 2012, Land & Improvements rose 2.17% year-over-year to $754.0 million; the TTM figure through Jan 2012 stood at $754.0 million (up 2.17% YoY), while the FY2012 annual figure was $754.0 million, up 2.17% from the prior year.
- Land & Improvements came in at $754.0 million for Q1 2012 at Johnson & Johnson, up from $738.0 million in the prior quarter.
- In the past five years, Land & Improvements ranged from a high of $754.0 million in Q1 2012 to a low of $738.0 million in Q1 2011.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 157.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 1, 2012 | 754.00 Mn |
| Jan 2, 2011 | 738.00 Mn |